AbbVie and Genmab reported Phase 3 success for Epkinly (Glofitamab) in first-line diffuse large B-cell lymphoma, reducing the risk of disease progression or death by nearly half versus chemotherapy alone. The companies said the results in intermediate- or high-risk patients exceeded expectations and cleared the path toward a potential standard-of-care expansion. The trial enrolled about 900 participants randomized to R-CHOP plus Epkinly or placebo, with the primary objective tied to extending lives or slowing disease progression. Investors reacted positively to the announcement, with the stock move reflecting market sensitivity to first-line readouts in the DLBCL setting. This result also tees up competition against Roche’s antibody-drug conjugate Polivy and adds pressure to the first-line treatment landscape where earlier accelerated approvals have already changed prescribing patterns.